FREE SHIPPING on orders over $100
Retatrutide
$200.00
Quantity
Customer Reviews
Write a review
Be the first one to review this product
certificate of analysis
Frequently Asked Questions
What is Retatrutide?
Retatrutide is an investigational peptide that acts as a triple agonist of GLP‑1, GIP, and glucagon receptors. It is being studied for its potential role in metabolic research.
How should Retatrutide be stored?
Lyophilized powder should be kept at −20°C. Once reconstituted, store at 2–8°C and avoid repeated freeze‑thaw cycles.
What is the half‑life of Retatrutide?
Approximately 6 days, making it suitable for weekly dosing in investigational protocols.
Is purity verified?
Yes. Each batch is tested for ≥99% purity, identity, and endotoxin levels. Certificates of Analysis (COA) are available upon request.
Is Retatrutide approved for clinical use?
No. Retatrutide is currently in Phase 3 trials and is designated Research Use Only.
Does the product come with instructions?
No. As a research peptide, it is supplied without dosing or administration guidance. It is not intended for human or animal consumption.
Overview
Retatrutide (LY3437943) is a novel triple incretin receptor agonist designed to activate GLP‑1, GIP, and glucagon receptors simultaneously. This unique profile makes it a promising investigational peptide for studying metabolic regulation, appetite control, and energy expenditure.
GLP‑1 receptor agonism: Enhances insulin secretion, slows gastric emptying, and reduces appetite.
GIP receptor agonism: Supports insulin sensitivity and lipid metabolism.
Glucagon receptor agonism: Increases energy expenditure and mobilizes stored fat.
Together, these mechanisms provide a synergistic platform for research into obesity, diabetes, and metabolic disease. Retatrutide is currently in Phase 3 clinical trials but remains investigational and unapproved for therapeutic use
History
Discovery: Retatrutide (LY3437943) was developed by Eli Lilly as part of their incretin research program.
Concept: Designed as a triple agonist of GLP‑1, GIP, and glucagon receptors to combine metabolic benefits.
Development Timeline: Entered clinical development in the early 2020s, with Phase 2 trials showing significant weight‑loss and metabolic improvements.
Current Status: Advancing through Phase 3 clinical trials for obesity and type 2 diabetes research.
Research Findings
Metabolic Regulation: Demonstrated reductions in appetite and improvements in glycemic control in preclinical models.
Energy Expenditure: Increased fat breakdown and reduced fat storage through glucagon receptor activation.
Weight Management: Investigational trials show promising results in obesity research.
Safety Profile: Still under evaluation; long half‑life (~6 days) supports weekly dosing in trial settings.
Molecular Structure
References
Jastreboff A.M. et al. (2023). Triple‑agonist Retatrutide in adults with obesity: Phase 2 trial results. New England Journal of Medicine, 389:514‑526.
Frias J.P. et al. (2022). Safety and efficacy of LY3437943, a novel triple agonist, in type 2 diabetes. Diabetes Care, 45(12):2893‑2902.
Eli Lilly & Co. (2023). Clinical pipeline update: Retatrutide (LY3437943). Company research disclosures.
Nauck M.A. et al. (2024). Incretin‑based therapies: expanding beyond GLP‑1 with dual and triple agonists. Diabetologia, 67:1123‑1135.
Consistent quality. Trusted supply.
Have a question? Contact Us
SMS: (855) 677-4736
66 W Flagler St Suite 900 PMB 11052, Miami Florida 33130
Verified compounds
Connect with Us
All products offered by Helix Source are intended strictly for laboratory, analytical, and research purposes. They are not for human consumption or clinical use of any kind. Statements on this site have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.
Helix Source is a chemical supplier, not a compounding pharmacy or outsourcing facility under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
For inquiries, contact us at (855) 677-4736 or [email protected].
Copyright© 2026 Helix Source - All Rights Reserved.